A carregar...
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
BACKGROUND: Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer (BCR) after radical prostatectomy. OBJECTIVE: To...
Na minha lista:
| Publicado no: | Eur Urol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4927410/ https://ncbi.nlm.nih.gov/pubmed/26743040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.12.013 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|